What's Included Tirzepatide activates both GLP-1 and GIP receptors for stronger appetite control, improved insulin sensitivity, and greater average weight loss in clinical trials
If the initial treatment plan is not producing the intended results, patients can request a follow-up assessment through the dashboard, and the provider can adjust the plan accordingly
For patients currently using retatrutide through research channels, transitioning from other GLP-1 medications requires careful dose mapping and expectation management regarding treatment duration
Hims & Hers Chief Commercial Officer Mike Chi told The Wall Street Journal that the goal of the ad was not only to talk to customers but to raise the issue among regulators, legislators, and those who can drive change. The Alliance of Pharmacy Compounders (APC) put out a statement in support of Hims & Hers' ad, noting that unlike FDA-approved drugs, which must comply with strict labeling requirements under the Federal Food, Drug, and Cosmetic Act, compounded medications have different rules for marketing and advertising
